Log in

Relevant bibliographies by topics / Cannabinoid type 2

Contents

Journal articles
Dissertations / Theses
Books
Book chapters
Conference papers
Reports

Academic literature on the topic 'Cannabinoid type 2'

Author: Grafiati

Published: 3 June 2025

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cannabinoid type 2.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Cannabinoid type 2"

1

Soraya, hiva, Ruohollah Seddigh, Fatemeh Hadi, and Mohammad Faramarzi. "Chemical cannabis; The New Trend of addiction in Iran." Iranian Journal of Psychiatry and Clinical Psychology 28, no. 1 (2022): 10. http://dx.doi.org/10.32598/ijpcp.28.1.4010.1.

Full text

Abstract:

Synthetic cannabinoids (SC) are a heterogeneous group of substances with a high affinity for cannabinoid receptors. Unlike Δ9-tetrahydrocannabinol (THC), synthetic cannabinoids are incredibly potent, highly productive, have more affinity for the Cannabinoid receptor type 1 (CB1), and Cannabinoid receptor type 2 (CB2), and are designed to accelerate the effects of tetrahydrocannabinol. Also, there is experimental evidence that SCs acts on non-cannabinoid receptors, such as the 5-HT2B receptor or dopaminergic receptors. (1, 2).

APA, Harvard, Vancouver, ISO, and other styles

2

Romero-Sandoval, Alfonso, and James C. Eisenach. "Spinal Cannabinoid Receptor Type 2 Activation Reduces Hypersensitivity and Spinal Cord Glial Activation after Paw Incision." Anesthesiology 106, no. 4 (2007): 787–94. http://dx.doi.org/10.1097/01.anes.0000264765.33673.6c.

Full text

Abstract:

Background Cannabinoids bind to cannabinoid receptors type 1 and 2 and produce analgesia in several pain models, but central side effects from cannabinoid 1 receptors limit their clinical use. Cannabinoid 2 receptors reduce inflammatory responses in the periphery by acting on immune cells, and they are present on glia in the central nervous system. This study tested whether spinal cannabinoid activation would induce analgesia, glial inhibition, and central side effects in a postoperative model or incisional pain. Methods Rats underwent paw incision surgery, with intrathecal injections of canna

APA, Harvard, Vancouver, ISO, and other styles

3

Walsh, Kenneth B., and Andrea E. Holmes. "Pharmacology of Minor Cannabinoids at the Cannabinoid CB1 Receptor: Isomer- and Ligand-Dependent Antagonism by Tetrahydrocannabivarin." Receptors 1, no. 1 (2022): 3–12. http://dx.doi.org/10.3390/receptors1010002.

Full text

Abstract:

(1) Background: In addition to the major phytocannabinoids, trans-Δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD), the cannabis plant (Cannabis sativa L.) synthesizes over 120 additional cannabinoids that are known as minor cannabinoids. These minor cannabinoids have been proposed to act as agonists and antagonists at numerous targets including cannabinoid type 1 (CB1) and type 2 (CB2) receptors, transient receptor potential (TRP) channels and others. The goal of the present study was to determine the agonist effects of the minor cannabinoids: cannabinol (CBN), cannabigerol (CBG), canna

APA, Harvard, Vancouver, ISO, and other styles

4

Twitchell, W., S. Brown, and K. Mackie. "Cannabinoids Inhibit N- and P/Q-Type Calcium Channels in Cultured Rat Hippocampal Neurons." Journal of Neurophysiology 78, no. 1 (1997): 43–50. http://dx.doi.org/10.1152/jn.1997.78.1.43.

Full text

Abstract:

Twitchell, W., S. Brown, and K. Mackie. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J. Neurophysiol. 78: 43–50, 1997. Cannabinoids and their analogues have been found to inhibit N- and P/Q-type Ca2+ currents in cell lines and sympathetic neurons transfected with cannabinoid CB1 receptor. However, the effects of cannabinoids on Ca2+ currents in the CNS are largely unexplored. In this study we investigated whether these compounds inhibit Ca2+ channels in cultured rat hippocampal neurons. With the use of antibodies directed against the amino-terminus

APA, Harvard, Vancouver, ISO, and other styles

5

Zong, Yuan, Xujiao Zhou, Jingyi Cheng, Jian Yu, Jihong Wu, and Chunhui Jiang. "Cannabinoids Regulate the Diameter of Pericyte-Containing Retinal Capillaries in Rats." Cellular Physiology and Biochemistry 43, no. 5 (2017): 2088–101. http://dx.doi.org/10.1159/000484193.

Full text

Abstract:

Background/Aims: Cannabinoids are vasoactive substances that act as key regulators of arterial tone in the blood vessels supplying peripheral tissues and the central nervous system. We therefore investigated the effect of cannabinoids on retinal capillaries and pericytes. Methods: The effects of cannabinoids on capillary diameters were determined using an ex vivo whole-mount rat retinal model. Western blotting, quantitative PCR, and immunohistochemistry were performed to explore the underlying mechanism. Results: Endogenous cannabinoid 2-arachidonoylglycerol and anandamide and exogenous cannab

APA, Harvard, Vancouver, ISO, and other styles

6

Storr, M., E. Gaffal, D. Saur, V. Schusdziarra, and H. D. Allescher. "Effect of cannabinoids on neural transmission in rat gastric fundus." Canadian Journal of Physiology and Pharmacology 80, no. 1 (2002): 67–76. http://dx.doi.org/10.1139/y02-005.

Full text

Abstract:

The purpose of this study was to examine the possible role of cannabinoids on the neuromuscular function of rat gastric fundus. In addition to possible direct effects on smooth muscle, the influence of cannabinoids on contractile (cholinergic) and relaxant (non-adrenergic, non-cholinergic (NANC)) neural innervation of the rat gastric fundus was investigated in vitro. Neither anandamide (an endogenous cannabinoid receptor agonist) nor Win 55,212-2 and methanandamide (synthetic cannabinoid receptor agonists) nor AM 630 (a cannabinoid receptor antagonist) showed any effect on smooth muscle activi

APA, Harvard, Vancouver, ISO, and other styles

7

Koay, Luan C., Rachael J. Rigby, and Karen L. Wright. "Cannabinoid-induced autophagy regulates suppressor of cytokine signaling-3 in intestinal epithelium." American Journal of Physiology-Gastrointestinal and Liver Physiology 307, no. 2 (2014): G140—G148. http://dx.doi.org/10.1152/ajpgi.00317.2013.

Full text

Abstract:

Autophagy is a catabolic process involved in homeostatic and regulated cellular protein recycling and degradation via the lysosomal degradation pathway. Emerging data associate impaired autophagy, increased activity in the endocannabinoid system, and upregulation of suppressor of cytokine signaling-3 (SOCS3) protein expression during intestinal inflammation. We have investigated whether these three processes are linked. By assessing the impact of the phytocannabinoid cannabidiol (CBD), the synthetic cannabinoid arachidonyl-2′-chloroethylamide (ACEA), and the endocannabinoid N-arachidonoylethan

APA, Harvard, Vancouver, ISO, and other styles

8

Park, Yu Mi, Charlotte Dahlem, Markus R. Meyer, Alexandra K. Kiemer, Rolf Müller, and Jennifer Herrmann. "Induction of Liver Size Reduction in Zebrafish Larvae by the Emerging Synthetic Cannabinoid 4F-MDMB-BINACA and Its Impact on Drug Metabolism." Molecules 27, no. 4 (2022): 1290. http://dx.doi.org/10.3390/molecules27041290.

Full text

Abstract:

Zebrafish (ZF; Danio rerio) larvae have become a popular in vivo model in drug metabolism studies. Here, we investigated the metabolism of methyl 2-[1-(4-fluorobutyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (4F-MDMB-BINACA) in ZF larvae after direct administration of the cannabinoid via microinjection, and we visualized the spatial distributions of the parent compound and its metabolites by mass spectrometry imaging (MSI). Furthermore, using genetically modified ZF larvae, the role of cannabinoid receptor type 1 (CB1) and type 2 (CB2) on drug metabolism was studied. Receptor-deficient

APA, Harvard, Vancouver, ISO, and other styles

9

Gonçalves, Elaine C. D., Gabriela M. Baldasso, Maíra A. Bicca, Rodrigo S. Paes, Raffaele Capasso, and Rafael C. Dutra. "Terpenoids, Cannabimimetic Ligands, beyond the Cannabis Plant." Molecules 25, no. 7 (2020): 1567. http://dx.doi.org/10.3390/molecules25071567.

Full text

Abstract:

Medicinal use of Cannabis sativa L. has an extensive history and it was essential in the discovery of phytocannabinoids, including the Cannabis major psychoactive compound—Δ9-tetrahydrocannabinol (Δ9-THC)—as well as the G-protein-coupled cannabinoid receptors (CBR), named cannabinoid receptor type-1 (CB1R) and cannabinoid receptor type-2 (CB2R), both part of the now known endocannabinoid system (ECS). Cannabinoids is a vast term that defines several compounds that have been characterized in three categories: (i) endogenous, (ii) synthetic, and (iii) phytocannabinoids, and are able to modulate

APA, Harvard, Vancouver, ISO, and other styles

10

Ellert-Miklaszewska, Aleksandra, Iwona Anna Ciechomska, and Bozena Kaminska. "Synthetic Cannabinoids Induce Autophagy and Mitochondrial Apoptotic Pathways in Human Glioblastoma Cells Independently of Deficiency in TP53 or PTEN Tumor Suppressors." Cancers 13, no. 3 (2021): 419. http://dx.doi.org/10.3390/cancers13030419.

Full text

Abstract:

Glioblastomas (GBMs) are aggressive brain tumors with frequent genetic alterations in TP53 and PTEN tumor suppressor genes rendering resistance to standard chemotherapeutics. Cannabinoid type 1 and 2 (CB1/CB2) receptor expression in GBMs and antitumor activity of cannabinoids in glioma cells and animal models, raised promises for a targeted treatment of these tumors. The susceptibility of human glioma cells to CB2-agonists and their mechanism of action are not fully elucidated. We determined CB1 and CB2 expression in 14 low-grade and 21 high-grade tumor biopsies, GBM-derived primary cultures a

APA, Harvard, Vancouver, ISO, and other styles

More sources

Dissertations / Theses on the topic "Cannabinoid type 2"

1

DE, DOMENICO EMANUELA. "Role of type-2 cannabinoid receptor in reproduction." Doctoral thesis, Università degli Studi di Roma "Tor Vergata", 2016. http://hdl.handle.net/2108/202948.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Sophocleous, Antonia. "Role of type 2 cannabinoid receptor in bone metabolism." Thesis, University of Edinburgh, 2009. http://hdl.handle.net/1842/5940.

Full text

Abstract:

Cannabinoid receptors play an important role in regulating bone mass and bone turnover. Studies in our laboratories have shown that young mice lacking type 1 cannabinoid receptor (CNR1-/-) had increased bone mass and were resistant to ovariectomy-induced bone loss. Other workers have reported that type 2 cannabinoid receptor knockout mice (CNR2-/-) develop age-related osteoporosis. The aim of this PhD thesis was to further investigate the role of CNR2 in bone metabolism in vitro and in vivo, using genetic and pharmacological approaches. This study showed that CNR2-/- mice had normal bone mass

APA, Harvard, Vancouver, ISO, and other styles

3

Netherland, Courtney Denise. "Role of Type 2 Cannabinoid Receptor (CB2) in Atherosclerosis." Digital Commons @ East Tennessee State University, 2011. https://dc.etsu.edu/etd/1392.

Full text

Abstract:

Atherosclerosis is a macrophage-dominated nonresolving inflammatory disease of the arterial wall. Macrophage processes, including apoptosis, influence lesion development in atherosclerosis. Cannabinoids, compounds structurally related to Δ9-tetrahydrocannabinol (THC), the active ingredient in marijuana, exert their effects through cannabinoid receptors, CB1 and CB2. Cannabinoid treatment, THC or Win55,212-2, reduces atherosclerosis in ApoE-null mice by a mechanism thought to involve CB2. However, the exact role of CB2 in atherosclerosis remains unclear. We found that CB2-null macrophages are r

APA, Harvard, Vancouver, ISO, and other styles

4

Fulmer, Makenzie. "Role of Cannabinoid Receptor Type 2 (CB2) in Late Stage Atherosclerosis." Digital Commons @ East Tennessee State University, 2017. https://dc.etsu.edu/etd/3328.

Full text

Abstract:

Atherosclerosis is a chronic inflammatory disorder of medium and large vessels. Immune signaling and dyslipidemia are two of several processes which influence lesion development in atherosclerosis. Cannabinoids, such as those found in marijuana, exert their effects through two cannabinoid receptors, CB1 and CB2. Recent studies using CB2 knockout mice and CB2-selective ligands have shed light on a protective role of CB2 in early stages of atherosclerosis. However, the role of CB2 in advanced stages of atherosclerosis remains unclear. To determine if CB2 plays a role in advanced atherosclerotic

APA, Harvard, Vancouver, ISO, and other styles

5

Moir, Michael. "The Design and Synthesis of Novel Selective Cannabinoid Receptor Type 2 Ligands." Thesis, The University of Sydney, 2019. https://hdl.handle.net/2123/21946.

Full text

Abstract:

The cannabinoid type 2 receptor (CB2R) is involved in the pathophysiology of numerous diseases. It is believed that in response to injury or damage, activation of CB2Rs triggers protective mechanisms for the resolution of inflammation and its associated symptoms. While many selective CB2R ligands have demonstrated promising results in pre-clinical animal models, no CB2R-based therapeutics are currently used in the clinic. Therefore, there is a grave need to develop novel, more efficacious and safer drugs that target the CB2R. Using a known pyrazolylidene benzamide agonist as a lead compound

APA, Harvard, Vancouver, ISO, and other styles

6

Hinshaw, Kaitlyn. "The Role of Type-2 Cannabinoid Receptors in Calcification of Atherosclerotic Lesions." Digital Commons @ East Tennessee State University, 2013. https://dc.etsu.edu/honors/98.

Full text

Abstract:

Introduction: Atherosclerosis is a chronic inflammatory disease characterized by the buildup of cholesterol, fat and other debris within arterial walls. Atherosclerotic lesions undergo a calcification process with similarities to bone remodeling. In mice, the type-2 cannabinoid receptor (CB2) is known to regulate bone remodeling processes and has also been shown to alter atherosclerotic lesion characteristics. However, the role of CB2 in lesion calcification is still unclear. CB2 modulates bone remodeling by affecting differentiation of osteogenic precursor cells; thus we hypothesize that CB2

APA, Harvard, Vancouver, ISO, and other styles

7

Stempel, Anna Vanessa [Verfasser]. "Cannabinoid type 2 receptors mediate a cell type-specific plasticity in the hippocampus / Anna Vanessa Stempel." Berlin : Freie Universität Berlin, 2015. http://d-nb.info/1080171088/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Stumpf, Alexander [Verfasser]. "Cannabinoid type 2 receptor-mediated cell type-specific self-inhibition in hippocampal and cortical neurons / Alexander Stumpf." Berlin : Freie Universität Berlin, 2019. http://d-nb.info/1190087871/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Fulmer, Makenzie L., Emilee Englehaupt, Chris Garst, and Stacy D. Brown. "Type 2 Cannabinoid Receptor Deficiency is Associated with Atherosclerotic Lesion Calcification in Ldr-null Mice." Digital Commons @ East Tennessee State University, 2016. https://dc.etsu.edu/etsu-works/5271.

Full text

Abstract:

Background: Calcification of atherosclerotic plaques is associated with vulnerability to rupture and increased risk of myocardial infarction. The mechanism of plaque calcification is unclear, but has been shown to be a cell-mediated process involving complex signaling pathways affecting the osteogenic transcription factor Runt-related transcription factor 2 (Runx2). The type-2 cannabinoid receptor (CB2) modulates processes involved in bone remodeling and our prior studies determined that CB2 alters the composition of early lesions in hyperlipidemic Ldlr-/- mice; however, the function of CB2 i

APA, Harvard, Vancouver, ISO, and other styles

10

Gazzi, Thais [Verfasser]. "Illuminating Protein-Targets: Design and Synthesis of New Optical Imaging Probes for Studies of the Cannabinoid Type 2 Receptor and Plectin-1 / Thais Gazzi." Berlin : Freie Universität Berlin, 2021. http://d-nb.info/1231276037/34.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Books on the topic "Cannabinoid type 2"

1

Hohmann, Andrea G. Control of pain initiation by endogenous cannabinoids. Edited by Paul Farquhar-Smith, Pierre Beaulieu, and Sian Jagger. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198834359.003.0033.

Full text

Abstract:

The landmark paper discussed in this chapter, published by Calignano et al. in 1998, focuses on the control of pain initiation by endogenous cannabinoids. In the paper, analgesic lipid mediators are shown to be present in peripheral paw tissue where they control the ability of pain signals to ascend to the central nervous system (CNS). Anandamide acts through a peripheral mechanism to suppress inflammatory pain via cannabinoid type 1 receptors. Palmitoylethanolamine, subsequently identified as an endogenous ligand for peroxisome proliferator-activated receptor-α‎, produces peripheral antinocic

APA, Harvard, Vancouver, ISO, and other styles

2

Nielsen, David A., Dmitri Proudnikov, and Mary Jeanne Kreek. The Genetics of Impulsivity. Edited by Jon E. Grant and Marc N. Potenza. Oxford University Press, 2012. http://dx.doi.org/10.1093/oxfordhb/9780195389715.013.0080.

Full text

Abstract:

Impulsivity is a complex trait that varies across healthy individuals, although when excessive, it is generally regarded as dysfunctional. Impulsive behavior may lead to initiation of drug addiction that interferes with inhibitory controls, which may in turn result in facilitation of the individual’s impulsive acts. Although environmental factors play a considerable role in impulsive behavior, a body of evidence collected in twin studies suggests that about 45% of the variance in impulsivity is accounted for by genetic factors. Genetic variants studied in association with impulsivity include t

APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Cannabinoid type 2"

1

Ciriaco, Fulvio, Nicola Gambacorta, Francesco Leonetti, Cosimo Damiano Altomare, and Orazio Nicolotti. "Virtual Reverse Screening Approach to Target Type 2 Cannabinoid Receptor." In Methods in Molecular Biology. Springer US, 2022. http://dx.doi.org/10.1007/978-1-0716-2728-0_40.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Guba, Wolfgang, Marc Nazaré, and Uwe Grether. "Chapter 4. Natural Compounds and Synthetic Drugs to Target Type-2 Cannabinoid (CB2) Receptor." In Drug Discovery. Royal Society of Chemistry, 2020. http://dx.doi.org/10.1039/9781839160752-00089.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Fujii, Mutsumi, Prativa Sherchan, Yoshiteru Soejima, Desislava Doycheva, Diana Zhao, and John H. Zhang. "Cannabinoid Receptor Type 2 Agonist Attenuates Acute Neurogenic Pulmonary Edema by Preventing Neutrophil Migration after Subarachnoid Hemorrhage in Rats." In Acta Neurochirurgica Supplement. Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-18497-5_24.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Abrams, Donald I., and Manuel Guzman. "Cannabinoids and Cancer." In Integrative Oncology. Oxford University PressNew York, NY, 2009. http://dx.doi.org/10.1093/oso/9780195309447.003.0007.

Full text

Abstract:

Abstract Cannabis has been used in medicine for thousands of years before achieving its current status as an illicit substance. Cannabinoids, the active components of Cannabis sativa, mimic the effects of the endogenous cannabinoids (the so-called endocannabinoids), activating specific cannabinoid receptors, particularly cannabinoid receptor type 1 (CB1) found predominantly in the central nervous system and cannabinoid receptor type 2 (CB2) found in cells involved with immune function. Delta-9-tetrahydrocannabinol, the main psychoactive cannabinoid in the plant, has been available as a prescri

APA, Harvard, Vancouver, ISO, and other styles

5

Pattabhiramaiah, Mahesh, and Shanthala Mallikarjunaiah. "Medical Cannabis in the Treatment of Epilepsy." In Medical Cannabis and the Effects of Cannabinoids on Fighting Cancer, Multiple Sclerosis, Epilepsy, Parkinson's, and Other Neurodegenerative Diseases. IGI Global, 2022. http://dx.doi.org/10.4018/978-1-6684-5652-1.ch004.

Full text

Abstract:

Epilepsy is one of the most known neurological diseases of therapeutic challenge. Medical marijuana/medicinal cannabis is a cannabinoid phytochemical derivative of the cannabis plant used for medical purposes in treating seizures and has increased sharply in current years. Cannabis plants contain over 100 cannabinoids, and evidence supports its practice in the treatment of a few childhood epilepsies. The active and major cannabinoids such as delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) exist in the cannabis plant and are the topic of the present study. Cannabinoids' biological acti

APA, Harvard, Vancouver, ISO, and other styles

6

Pattabhiramaiah, Mahesh, Shanthala Mallikarjunaiah, and Baishali Bedi Sarma. "Pros and Cons of Cannabinoids as a Potential Therapeutic Target for Treating Parkinson's Disease." In Medical Cannabis and the Effects of Cannabinoids on Fighting Cancer, Multiple Sclerosis, Epilepsy, Parkinson's, and Other Neurodegenerative Diseases. IGI Global, 2022. http://dx.doi.org/10.4018/978-1-6684-5652-1.ch009.

Full text

Abstract:

Medical marijuana or cannabis is a psychedelic drug composed of highly lipophilic tetrahydrocannabinol (THC) and cannabidiol (CBD) components derived from the plant C. sativa and C. indica. Parkinson's disease (PD), in which interactivity of biochemical and cellular signaling pathways induces endogenous cannabinoid system, a neuromodulatory system, transmits specific physiological effects when coupled with G-protein-coupled receptor (GPCR) via type 1 cannabinoid receptor (CB1) and type 2 cannabinoid receptor (CB2). Much recent research indicates that interactions between the cannabis system an

APA, Harvard, Vancouver, ISO, and other styles

7

Oddi, Sergio, Paola Spagnuolo, Monica Bari, Antonella D'Agostino, and Mauro Maccarrone. "Differential Modulation of Type 1 and Type 2 Cannabinoid Receptors along the Neuroimmune Axis." In International Review of Neurobiology. Elsevier, 2007. http://dx.doi.org/10.1016/s0074-7742(07)82017-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Abellanas, Miguel A., and Maria S. Aymerich. "Cannabinoid receptor type 2 as a therapeutic target for Parkinson's disease." In Diagnosis and Management in Parkinson's Disease. Elsevier, 2020. http://dx.doi.org/10.1016/b978-0-12-815946-0.00033-8.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

S., Matthew, Christian Ndong, Russell P. Landry III, Joyce A., and E. Alfonso. "Reduced Antinociceptive Effect of Repeated Treatment with a Cannabinoid Receptor Type 2 Agonist in Cannabinoid-Tolerant Rats Following Spinal Nerve Transection." In Pain Management - Current Issues and Opinions. InTech, 2012. http://dx.doi.org/10.5772/31686.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Chacur, Marucia, Karina Henrique Binda, and Caroline C. Real. "Exercise and Parkinson’s disease: Linking in the cannabinoid type 1 (CB1) and type 2 (CB2) and mu-opioid receptors." In Neurobiology and Physiology of the Endocannabinoid System. Elsevier, 2023. http://dx.doi.org/10.1016/b978-0-323-90877-1.00028-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Cannabinoid type 2"

1

Chen, Kristen, Majid Zeidi, Nithin Reddy, Barbara White, and Victoria Werth. "FRI0307 LENABASUM, A CANNABINOID TYPE 2 RECEPTOR AGONIST, REDUCES CD4 CELL POPULATIONS AND DOWNREGULATES TYPE 1 AND 2 INTERFERON ACTIVITIES IN LESIONAL DERMATOMYOSITIS SKIN." In Annual European Congress of Rheumatology, EULAR 2019, Madrid, 12–15 June 2019. BMJ Publishing Group Ltd and European League Against Rheumatism, 2019. http://dx.doi.org/10.1136/annrheumdis-2019-eular.7759.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Werth, V. P., E. Hejazi, S. M. Pena, et al. "FRI0470 A phase 2 study of safety and efficacy of lenabasum (JBT-101), a cannabinoid receptor type 2 agonist, in refractory skin-predominant dermatomyositis." In Annual European Congress of Rheumatology, EULAR 2018, Amsterdam, 13–16 June 2018. BMJ Publishing Group Ltd and European League Against Rheumatism, 2018. http://dx.doi.org/10.1136/annrheumdis-2018-eular.3531.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

"O-007 - PRESCRIPTION PATTERNS ON PATIENTS WITH DUAL DIAGNOSIS: A RETROSPECTIVE INPATIENT ANALYSIS." In 24 CONGRESO DE LA SOCIEDAD ESPAÑOLA DE PATOLOGÍA DUAL. SEPD, 2022. http://dx.doi.org/10.17579/abstractbooksepd2022.o007.

Full text

Abstract:

Introduction. Dual diagnosis (DD) refers to the simultaneous diagnosis of a psychiatric disorder and a substance use disorder (SUD). The prevalence rate is considerably high in patients with schizophrenia and affective disorders; it predicts a more severe illness course, with decreased adherence to treatment and higher rates of hospitalization. As such, there is a growing demand for clinical guidelines and treatment consensus for these patients. In this retrospective analysis, we aimed to examine if and how prescription patterns in DD differ regarding psychiatric diagnosis and type of substanc

APA, Harvard, Vancouver, ISO, and other styles

4

Jugl, Sebastian, Aimalohi Okpeku, Brianna Costales, et al. "A Mapping Literature Review of Medical Cannabis Clinical Outcomes and Quality of Evidence in Approved Conditions in the United States, from 2016 to 2019." In 2020 Virtual Scientific Meeting of the Research Society on Marijuana. Research Society on Marijuana, 2021. http://dx.doi.org/10.26828/cannabis.2021.01.000.25.

Full text

Abstract:

Background: Medical cannabis is available to patients by physician order in two-thirds of the United States (U.S.) as of 2020, but remains classified as an illicit substance by federal law. States that permit medical cannabis ordered by a physician typically require a diagnosed medical condition that is considered qualifying by respective state law. Objectives: To identify and map the most recently (2016-2019) published clinical and scientific literature across approved conditions for medical cannabis, and to evaluate the quality of identified recent systematic reviews. Methods: Literature sea

APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Cannabinoid type 2"

1

Chou, Roger, Azrah Y. Ahmed, Tracy Dana, et al. Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2024 Update. Agency for Healthcare Research and Quality (AHRQ), 2024. https://doi.org/10.23970/ahrqepccer250.2024update.

Full text

Abstract:

Objectives. To update the evidence on benefits and harms of cannabinoids and other plant-based compounds to treat subacute and chronic pain in adults and adolescents using a living systematic review approach. Data sources. Ovid® MEDLINE®, PsycINFO®, Embase®, the Cochrane Library, and SCOPUS® databases, and reference lists of included studies were searched to June 30, 2024. Review methods. We grouped studies based on their tetrahydrocannabinol (THC) to cannabidiol (CBD) ratio and by product type: synthetic, purified (plant-derived product consisting of a single cannabinoid, e.g., dronabinol or

APA, Harvard, Vancouver, ISO, and other styles

2

Chou, Roger, Azrah Y. Ahmed, Benjamin J. Morasco, et al. Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain: 2023 Update. Agency for Healthcare Research and Quality, 2023. http://dx.doi.org/10.23970/ahrqepccer250update2023.

Full text

Abstract:

Objectives. To update the evidence on benefits and harms of cannabinoids and other plant-based compounds to treat sub-acute and chronic pain in adults and adolescents using a living systematic review approach. Data sources. Ovid® MEDLINE®, PsycINFO®, Embase®, the Cochrane Library, and SCOPUS® databases; and reference lists of included studies were searched to April 23, 2023. Review methods. An updated protocol with expanded inclusion criteria (addition of sub-acute [4 to 12 weeks’ duration] pain and adolescents) was posted on the PROSPERO registry. We grouped studies based on their THC to CBD

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!